Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of serum PSA in breast cancer patients.
|
31664946 |
2019 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Differences were detected in the completion of screening tests for colorectal cancer (p < 0.001), breast cancer (p = 0.023), cervical cancer (p = 0.006), and prostate-specific antigen determination (p < 0.001) in relation to the participants' academic profiles.
|
31848937 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We screened 13 well-characterized breast cancer cell lines for hK2 and PSA production upon <i>in vitro</i> hormone stimulation by testosterone [dihydrotestosterone (DHT)].
|
30254080 |
2019 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current smoking (RR=0.86, 0.83-0.90), non-participation in breast cancer screening (female) or PSA testing (male) (RR=0.84, 0.81-0.86), poor self-reported health (RR=0.89, 0.86-0.91), lower levels of education (RR=0.91, 0.90-0.93), and not speaking English at home (RR=0.88, 0.85-0.91) were associated with reduced ever-uptake of screening within the NBCSP and of any CRC screening.
|
29109015 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
( n = 73); 2) Angina: treatment options ( n = 88); 3) Breast cancer: surgical options ( n = 265); 4) Prostate Specific Antigen (PSA) test: yes or no?
|
29078054 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To account for unmeasured factors, the correlation between changes in PSA screening over time and changes in screening for colorectal and breast cancer were assessed.All analyses were conducted in 2016.
|
29056579 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum PSA could be a useful biomarker for the diagnosis of breast cancer, and a biomarker for the differential diagnosis of breast cancer from benign breast tumors.
|
30024607 |
2018 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Retrospective inception cohort study of male Veterans aged 40 to 89 years with a laboratory-defined low testosterone measurement from 2002 to 2011 and recent prostate specific antigen (PSA) testing; excluding those with recent testosterone treatment, prostate or breast cancer, high PSA or prior prostate biopsy.
|
29933385 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results obtained indicated PSA species common to BCa, PCa, and BPH at 12-13 kDa, 17-19 kDa and 21-24 kDa.
|
30581329 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The substantial decrease in breast cancer mortality in women below regular screening age and the reductions in mortality from both cancers in Denmark from the mid-1990s are consistent with beneficial contributions from improved treatment besides mammography screening and increased PSA testing.
|
28795403 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers.
|
25746941 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of CRC screening tests was significantly lower than mammography for breast cancer detection in women (20 vs. 82%, P<0.001) and use of serum prostate-specific antigen for prostate cancer detection in men (27 vs. 46%, P<0.001).
|
21989122 |
2011 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the relationship between telomerase activity and PSA gene expression with steroid hormone receptors in breast cancer patients.
|
22329196 |
2011 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interaction between estrogens and androgen receptor genes microsatellites, prostate-specific antigen and androgen receptor expressions in breast cancer.
|
20353269 |
2010 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era.
|
18646000 |
2008 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer cell lines were treated with various steroid hormones and kallikrein (KLK/hK) expression of hK3 (prostate-specific antigen, PSA), hK5, hK6, hK7, hK8, hK10, hK11, hK13, and hK14 was analyzed at the RNA level via RT-PCR and at the protein level by immunofluorometric ELISA assays.
|
16897430 |
2007 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot study was performed using both EST and SAGE vNorthern to analyze the expression of a panel of known genes, including high abundance genes beta-actin and G3PDH, low abundance genes BRCA1 and p53, tissue-specific genes CEA and PSA and two breast cancer-related genes Her2/neu and MUC1.
|
15647832 |
2005 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no significant association between the PSA gene polymorphism and breast cancer risk, nor was there significant gene-gene interaction.
|
16365023 |
2005 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the presence of the A-AA allele at the PSA promoter region is associated with less aggressive forms of breast cancer and could be looked on as a favorable prognostic factor.
|
12168876 |
2002 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, highest levels were seen in prostatic tissue extracts and seminal plasma. hK11 in seminal plasma and prostatic extracts is present at approximately 300-fold lower levels than prostate-specific antigen and at approximately the same levels as hK2. hK11 expression in breast cancer cell lines is up-regulated by estradiol.
|
11782391 |
2002 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Like KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line.
|
11948967 |
2002 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate specific antigen has recently been shown to be an independent favourable prognostic marker for breast cancer.
|
12439720 |
2002 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Every breast cancer cell line exhibited a distinct expression pattern of the nuclear receptor co-regulators examined raising the possibility that the relative levels of these co-activators/-repressors might differentially modulate androgen receptor transcriptional activity within the promoter/enhancer region of KLK2 and KLK3 of these cells.
|
12124798 |
2002 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Like the genes that encode PSA and other kallikreins, the KLK5 gene was found to be regulated by steroid hormones in the BT-474 breast cancer cell line.
|
12142380 |
2002 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The (TA)(9) allele has been reported to be associated with higher serum prostate-specific antigen levels in breast tumors and lower risk of relapse in breast cancer patients and more recently has also been reported to be linked to the codon 89 valine variant, which is itself associated with higher serum prostate-specific antigen levels in breast tumors and a more favorable breast cancer prognosis.
|
11751447 |
2001 |